About: Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 06 June 2013

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) наукова стаття, опублікована в червні 2013 (uk) مقالة علمية نشرت في 06 يونيو 2013 (ar) scientific article published on 06 June 2013 (en) artículu científicu espublizáu en xunu de 2013 (ast)
publication date	wds:Q37088281-D60376EE-735A-4055-AB01-640BDB37EC90
publication date	2013-06-06 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37088281-8E1F0003-7ACF-4F29-B865-C77582E21039
language of work or name	English
cites work	wds:Q37088281-071CD22D-1974-4D11-B0D1-8F4713B7798F wds:Q37088281-08DF7D20-4A80-4A30-9017-1CECAD1D09C3 wds:Q37088281-1C39CF6D-16DC-4C22-8ED4-EC9CF0BF2327 wds:Q37088281-222B6DCE-8F92-437A-8B89-2D5E5296DBD8 wds:Q37088281-23ED52B5-C3B7-4DC3-9D39-FC2BEA32153E wds:Q37088281-2752B0EF-8585-4303-A6FE-4D11A489CCF9 wds:Q37088281-2FB36C8A-1A38-4012-98B6-EB4EC4465A18 wds:Q37088281-3B58BCF5-E547-4F1F-BE7E-BD977B6615B7 wds:Q37088281-47F72302-65BE-41D6-879E-9EC2E1A04DEC wds:Q37088281-4847F264-19FF-4B58-A240-AB844FD87D98 wds:Q37088281-53E5331C-8576-4AEB-88E7-927823E9F6B5 wds:Q37088281-7108C4F3-96CC-4144-9D3D-F85A932B1AD9 wds:Q37088281-75A0CE0D-C7F7-4A55-A000-5E00522D9EEA wds:Q37088281-9057385D-0440-4EF7-880A-1158DC0F1EEF wds:Q37088281-94F8DAC5-DF99-4E39-A384-74900A97927F wds:Q37088281-CA1BCC90-1A41-4EBA-A85C-A2898AD51447 wds:Q37088281-DA9711FB-5107-4B02-8A7B-505C848A2A61 wds:Q37088281-EC5237FB-3D30-4B68-AF9C-A0C5289F71C0 wds:Q37088281-FE287644-93CB-4F05-A96E-C8E68B0FC72B
cites work	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. A concordance correlation coefficient to evaluate reproducibility Safety, activity, and immune correlates of anti-PD-1 antibody in cancer Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Reporting results of cancer treatment Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST
author name string	wds:Q37088281-61568375-B99B-4CCD-A8B2-4FDCD4C320D9 wds:Q37088281-A7637772-E661-4721-A32C-03DB05715376 wds:Q37088281-B6A1E06C-915F-4AE8-9463-E68CDF2D50A4 wds:Q37088281-C44BDECB-1F46-4EC0-9942-618AA898F0B0
author name string	Nikhil H Ramaiya Mizuki Nishino Maria Gargano Margaret Suda
rdfs:label	Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements (en) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements (nl)
skos:prefLabel	Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements (en) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements (nl)
name	Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements (en) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements (nl)
author	wds:Q37088281-7903CE6B-0D45-408B-AF25-CDE8A2C61EE4 wds:Q37088281-A6083721-9A09-43EC-82AC-ACB21C2A53B0
author	F Stephen Hodi Anita Giobbie-Hurder
title	wds:Q37088281-C965621B-64C8-4C65-A3E3-53BAC6D6EE80
title	Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements (en)
page(s)	wds:Q37088281-D66BD231-8869-47A6-A983-BE897D9FEF43
page(s)	3936-3943
instance of	wds:Q37088281-F5292990-3CD1-4C5E-836C-67C74E12A88E
instance of	scholarly article
main subject	wds:Q37088281-F2F40AEB-817E-4AFB-8E78-F39F37D8F41F
main subject	immunotherapy
PubMed ID	wds:Q37088281-FE11F51B-B6AE-4809-A0C8-13B9A60132A3
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/23743568
PubMed ID	23743568
published in	wds:Q37088281-A421671C-11BC-4092-A8CF-5950A770143F
published in	Clinical Cancer Research
issue	wds:Q37088281-10DA4F1E-482A-4EFC-ABB5-4589937119B6
volume	wds:Q37088281-4C636311-5534-45AA-9D74-97AF87F864D4
issue	14
volume	19
DOI	wds:Q37088281-BC46B411-88B7-473A-9D1B-097AB5BCED11
DOI	http://dx.doi.org/10.1158/1078-0432.CCR-13-0895
DOI	10.1158/1078-0432.CCR-13-0895
Fatcat ID	wds:Q37088281-2A7CB324-DE6F-4738-A994-428F277EBF9D
Fatcat ID	release_oeqpmbhorzgzxoy6i7goxyruq4
PMCID	wds:Q37088281-6D3E6A03-83E8-480A-A37D-F47F3A403728

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software